Clinical trials: Hepatitis; Epidemic
Chronic Hepatitis C
Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin
This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.
- Trial name
- NCT00395421
- Testing
- NM283 plus Peg-IFNα-2a
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Vitamin D Treatment in Patients With Chronic Hepatitis C
We hypothesize that patients with Ch.HCV have a low level of vitamin D, and that by raising their vitamin D levels by adding it to their standard treament of Pegylated Interferon and Ribavirin, there will be an increase in their…
- Trial name
- NCT00804752
- Testing
- Adding vitamin D, Vitamin D
- Where
- Israel
- Sponsor
- Hillel Yaffe Medical Center
Hepatitis E
A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults
Hepatitis E is characteristic by sporadic and local epidemic around the world, and mainly infects adults aged 15 to 40 years old, resulting in the infection rate ranged from 1% to 15%.
- Trial name
- NCT02603055
- Testing
- 30μg/0.5ml Hepatitis E vaccine, 30μg/0.5ml Recombinant Hepatitis E vaccine
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Chronic Hepatitis C
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
- Trial name
- NCT00372385
- Testing
- Ribavirin, Pegylated Interferon Alfa 2a, Telaprevir
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 334 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis B Virus Related Cirrhosis
Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV
Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of Liver cirrhosis in China.
- Trial name
- NCT02241616
- Testing
- Entecavir+Fuzheng Huayu+TCM Granule
- Where
- 20 sites in China
- Volunteers
- 350 people
- Sponsor
- ShuGuang Hospital
Hepatitis B， Chronic
Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers
To evaluate the safety and tolerability of Hepalatide(L47) and characterize the clinical pharmacokinetics in healthy volunteers.
- Trial name
- NCT02612506
- Testing
- Hepalatide
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Lung Diseases
Transplanting Hepatitis C Lungs Into Negative Lung Recipients
This study is being conducted to determine safety and effectiveness of transplanting lungs from Hepatitis C-positive donors into Hepatitis C-negative patients on the lung transplant waitlist, who will then be treated with…
- Trial name
- SHELTER (NCT03724149)
- Testing
- Zepatier, Epclusa
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Liver Cirrhosis, Experimental
Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
To evaluate: 1. the impact of combined antiviral therapy (Peginterferon plus ribavirin) on natural history of patients affected with HCV decompensated cirrhosis, after sustained virological response. A controlled study. 2.
- Trial name
- NCT00301509
- Testing
- peginterferon and ribavirin
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
End Stage Renal Disease, Hepatitis C
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time.
- Trial name
- NCT03627299
- Testing
- 300mg glecaprevir/pibrentasivir 120mg
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Johns Hopkins University
Alcoholic Hepatitis
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
- Trial name
- AHFIRM (NCT04563026)
- Testing
- DUR-928 30 mg, DUR-928 90 mg
- Where
- 68 sites in United States, Australia and 4 more
- Volunteers
- 307 people
- Sponsor
- Durect
Combined Point of Care Diagnostic of HIV, HBV and HCV
Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C
Prospective, cross-sectional, adaptative study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA IBC (a Multiplex Point-of-Care Test for the detection of HIV, HBV and HCV) in detecting anti-HIV…
- Trial name
- MAGICIEN (NCT06082336)
- Testing
- MagIA IBC test in capillary blood, MagIA IBC test in other blood matrices
- Where
- 2 sites in France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- MagIA Diagnostics
Autoimmune Diseases
Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis
Separated and expanded the CD4+CD25+CD127- Tregs from peripheral blood of autoimmune hepatitis patients and administrate the cells (5 x 106 cells/kg) into patients.
- Trial name
- Treg (NCT02704338)
- Testing
- Regulatory T cells
- Volunteers
- 30 people
- Sponsor
- Nanjing Medical University
Hepatitis C
A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects
This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor (NNI) in healthy volunteers and HCV infected individuals
- Trial name
- NCT02760758
- Testing
- CDI-31244
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Cocrystal Pharma, Inc.
Chronic Hepatitis B, Nonalcoholic Fatty Liver Disease
Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD
The changes in liver function, body mass index, controlled attenuation parameters, liver stiffness and HBV-DNA at different time points in each group before and after treatment were counted to explore the clinical efficacy of…
- Trial name
- NCT05523648
- Testing
- Chronic Hepatitis B
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sichuan Leshan Traditional Chinese Medicine Hospital
Hepatitis C, Chronic
A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)
This open-label, non-comparative study will assess the safety and tolerability of individualized combination therapy with Copegus (ribavirin) and Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C.
- Trial name
- NCT01296971
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B
This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B.
- Trial name
- EVD (NCT00710216)
- Testing
- Lamivudine, Telbivudine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Ulm
Hematopoietic Stem Cell Transplantation
Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.
The prevalence of Hepatitis C Virus (HCV) infection was reported to range between 10% and up to 30% prior to institution of routine HCV screening in recipients of HCT (hematopoietic cell transplantation).
- Trial name
- NCT03279133
- Testing
- Ledipasvir 90mg/Sofosubvir 400mg
- Where
- 2 sites in United States
- Sponsor
- Kaiser Permanente
Cystic Fibrosis, Hepatitis A
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization…
- Conditions
- Cystic Fibrosis, Hepatitis A, Hepatitis B, Tuberculosis
- Trial name
- NCT02605538
- Testing
- Vaccination with vaccine against hepatitis A and B
- Where
- Sweden
- Volunteers
- healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Chronic Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3
A Study of Albuferon with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3.
- Trial name
- NCT00656006
- Testing
- Albuferon, Ribavirin
- Where
- 6 sites in Canada
- Volunteers
- 43 people
- Sponsor
- Human Genome Sciences Inc.
Hepatitis C, RDT
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania
The goal of this non-randomised, quasi-experimental, prospective comparative trial is to trial simplified care pathways for hepatitis C testing and treatment for people who inject drugs in Armenia, Georgia, and Tanzania.
- Trial name
- CUTTS HepC (NCT06159504)
- Testing
- sofosbuvir/velpatasvir (SOF/VEL), Shortened read time of rapid diagnostic test for hepatitis C virus.
- Where
- Armenia
- Volunteers
- 3,040 people
- Sponsor
- Médecins du Monde
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.